Tech Company Financing Transactions

Cyteir Therapeutics Funding Round

On 2/12/2021, Cyteir Therapeutics secured $80 million in Series C funding from RA Capital, Acuta Capital and Ally Bridge Group.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series C
Proceeds Purpose
The company will use the new funds to advance its lead compound, the first-in-class inhibitor of RAD51-mediated DNA repair, CYT-0851, into phase 2 monotherapy trials in hematologic cancers and solid tumors, to initiate trials combining CYT-0851 with other cancer therapies, and to expand preclinical research to identify and advance additional novel cancer therapies.

Company Information

Company Status
Mailing Address
128 Spring St. Building A 510
Lexington, MA 02421
Email Address
DNA damage and genomic instability are hallmarks of cancer and autoimmune diseases. This makes the disease-causing cells highly sensitive to drugs that target specific DNA repair factors. This is termed synthetic lethality.
Cyteir Therapeutics LinkedIn Company Profile
Social Media
Cyteir Therapeutics Company Twitter Account
Company News
Cyteir Therapeutics News
Cyteir Therapeutics on Facebook
Cyteir Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Markus Renschler
  Markus Renschler LinkedIn Profile  Markus Renschler Twitter Account  Markus Renschler News  Markus Renschler on Facebook
Chief Scientific Officer
Paul Secrist
  Paul Secrist LinkedIn Profile  Paul Secrist Twitter Account  Paul Secrist News  Paul Secrist on Facebook
Vice President
Jean-Marc Lapierre
  Jean-Marc Lapierre LinkedIn Profile  Jean-Marc Lapierre Twitter Account  Jean-Marc Lapierre News  Jean-Marc Lapierre on Facebook
Vice President
Thomas O'Shea
  Thomas O'Shea LinkedIn Profile  Thomas O'Shea Twitter Account  Thomas O'Shea News  Thomas O'Shea on Facebook
VP - Bus. Development
Andrew Gengos
  Andrew Gengos LinkedIn Profile  Andrew Gengos Twitter Account  Andrew Gengos News  Andrew Gengos on Facebook
VP - Operations
Susan Doleman
  Susan Doleman LinkedIn Profile  Susan Doleman Twitter Account  Susan Doleman News  Susan Doleman on Facebook
VP - R & D
Judson Englert
  Judson Englert LinkedIn Profile  Judson Englert Twitter Account  Judson Englert News  Judson Englert on Facebook
VP - R & D
Barbara Wan
  Barbara Wan LinkedIn Profile  Barbara Wan Twitter Account  Barbara Wan News  Barbara Wan on Facebook



Browse more venture capital transactions:

Prev: 2/12/2021: Ensoma venture capital transaction
Next: 2/12/2021: Intenseye venture capital transaction


Share this article


News on VC Transactions

Our team works diligently to document every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary